In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation

In Sook Kim, Yoon Mi Song, Tae Hyung Cho, Yongdoo Park, Kyu Back Lee, Insup Noh, Franz Weber, Soon Jung Hwang

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A number of factors must be added to human bone marrow stromal cells (hBMSCs) in vitro to induce osteogenesis, including ascorbic acid (AA), β-glycerophosphate (GP), and dexamethasone (Dex). Bone morphogenic protein (BMP)-2 is an osteoinductive factor that can commit stromal cells to differentiate into osteoblasts. However, it is still not clear whether the addition of BMP-2 alone in vitro can induce hBMSCs to complete osteoblast differentiation, resulting in matrix mineralization. This study compares the effects of BMP-2 and Dex, alone and combined, on the early and late stages of hBMSC differentiation. We found that BMP-2 causes a significant induction of alkaline phosphatase (ALP) activity in hBMSCs, with a transcriptional upregulation of known BMP-2-responsive genes, and the stable expression of cbfa1 in the nucleus and the regions surrounding the nucleus in the early phase of osteoblast differentiation. However, continuous treatment with BMP-2 alone at doses ranging from 100 to 300 ng/mL results in a less efficient enhancement of in vitro matrix mineralization, despite a significant induction of ALP activity at a concentration of 100 ng/mL. Our results reflect how the effects of BMP-2 on hBMSCs can vary depending on the stage of osteoblast differentiation, and highlight the need to understand the role of BMP-2 in primary hBMSCs derived from diverse sources in order to increase the efficiency of using BMP-2 in osteoinductive therapies.

Original languageEnglish
Pages (from-to)553-564
Number of pages12
JournalDevelopment Growth and Differentiation
Volume50
Issue number7
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Osteoblasts
Mesenchymal Stromal Cells
Bone and Bones
Proteins
Dexamethasone
Alkaline Phosphatase
Glycerophosphates
In Vitro Techniques
Stromal Cells
Osteogenesis
Human Activities
Ascorbic Acid
Cell Differentiation
Up-Regulation
Gene Expression

Keywords

  • Alkaline phosphatase
  • Bone morphogenic protein-2
  • Human bone marrow stromal cells
  • In vitro matrix mineralization
  • Osteoblast differentiation

ASJC Scopus subject areas

  • Anatomy
  • Developmental Biology
  • Cell Biology

Cite this

In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation. / Kim, In Sook; Song, Yoon Mi; Cho, Tae Hyung; Park, Yongdoo; Lee, Kyu Back; Noh, Insup; Weber, Franz; Hwang, Soon Jung.

In: Development Growth and Differentiation, Vol. 50, No. 7, 01.09.2008, p. 553-564.

Research output: Contribution to journalArticle

@article{2a1d2fa61d794dc985a6aceac7d25231,
title = "In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation",
abstract = "A number of factors must be added to human bone marrow stromal cells (hBMSCs) in vitro to induce osteogenesis, including ascorbic acid (AA), β-glycerophosphate (GP), and dexamethasone (Dex). Bone morphogenic protein (BMP)-2 is an osteoinductive factor that can commit stromal cells to differentiate into osteoblasts. However, it is still not clear whether the addition of BMP-2 alone in vitro can induce hBMSCs to complete osteoblast differentiation, resulting in matrix mineralization. This study compares the effects of BMP-2 and Dex, alone and combined, on the early and late stages of hBMSC differentiation. We found that BMP-2 causes a significant induction of alkaline phosphatase (ALP) activity in hBMSCs, with a transcriptional upregulation of known BMP-2-responsive genes, and the stable expression of cbfa1 in the nucleus and the regions surrounding the nucleus in the early phase of osteoblast differentiation. However, continuous treatment with BMP-2 alone at doses ranging from 100 to 300 ng/mL results in a less efficient enhancement of in vitro matrix mineralization, despite a significant induction of ALP activity at a concentration of 100 ng/mL. Our results reflect how the effects of BMP-2 on hBMSCs can vary depending on the stage of osteoblast differentiation, and highlight the need to understand the role of BMP-2 in primary hBMSCs derived from diverse sources in order to increase the efficiency of using BMP-2 in osteoinductive therapies.",
keywords = "Alkaline phosphatase, Bone morphogenic protein-2, Human bone marrow stromal cells, In vitro matrix mineralization, Osteoblast differentiation",
author = "Kim, {In Sook} and Song, {Yoon Mi} and Cho, {Tae Hyung} and Yongdoo Park and Lee, {Kyu Back} and Insup Noh and Franz Weber and Hwang, {Soon Jung}",
year = "2008",
month = "9",
day = "1",
doi = "10.1111/j.1440-169X.2008.01052.x",
language = "English",
volume = "50",
pages = "553--564",
journal = "Development Growth and Differentiation",
issn = "0012-1592",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation

AU - Kim, In Sook

AU - Song, Yoon Mi

AU - Cho, Tae Hyung

AU - Park, Yongdoo

AU - Lee, Kyu Back

AU - Noh, Insup

AU - Weber, Franz

AU - Hwang, Soon Jung

PY - 2008/9/1

Y1 - 2008/9/1

N2 - A number of factors must be added to human bone marrow stromal cells (hBMSCs) in vitro to induce osteogenesis, including ascorbic acid (AA), β-glycerophosphate (GP), and dexamethasone (Dex). Bone morphogenic protein (BMP)-2 is an osteoinductive factor that can commit stromal cells to differentiate into osteoblasts. However, it is still not clear whether the addition of BMP-2 alone in vitro can induce hBMSCs to complete osteoblast differentiation, resulting in matrix mineralization. This study compares the effects of BMP-2 and Dex, alone and combined, on the early and late stages of hBMSC differentiation. We found that BMP-2 causes a significant induction of alkaline phosphatase (ALP) activity in hBMSCs, with a transcriptional upregulation of known BMP-2-responsive genes, and the stable expression of cbfa1 in the nucleus and the regions surrounding the nucleus in the early phase of osteoblast differentiation. However, continuous treatment with BMP-2 alone at doses ranging from 100 to 300 ng/mL results in a less efficient enhancement of in vitro matrix mineralization, despite a significant induction of ALP activity at a concentration of 100 ng/mL. Our results reflect how the effects of BMP-2 on hBMSCs can vary depending on the stage of osteoblast differentiation, and highlight the need to understand the role of BMP-2 in primary hBMSCs derived from diverse sources in order to increase the efficiency of using BMP-2 in osteoinductive therapies.

AB - A number of factors must be added to human bone marrow stromal cells (hBMSCs) in vitro to induce osteogenesis, including ascorbic acid (AA), β-glycerophosphate (GP), and dexamethasone (Dex). Bone morphogenic protein (BMP)-2 is an osteoinductive factor that can commit stromal cells to differentiate into osteoblasts. However, it is still not clear whether the addition of BMP-2 alone in vitro can induce hBMSCs to complete osteoblast differentiation, resulting in matrix mineralization. This study compares the effects of BMP-2 and Dex, alone and combined, on the early and late stages of hBMSC differentiation. We found that BMP-2 causes a significant induction of alkaline phosphatase (ALP) activity in hBMSCs, with a transcriptional upregulation of known BMP-2-responsive genes, and the stable expression of cbfa1 in the nucleus and the regions surrounding the nucleus in the early phase of osteoblast differentiation. However, continuous treatment with BMP-2 alone at doses ranging from 100 to 300 ng/mL results in a less efficient enhancement of in vitro matrix mineralization, despite a significant induction of ALP activity at a concentration of 100 ng/mL. Our results reflect how the effects of BMP-2 on hBMSCs can vary depending on the stage of osteoblast differentiation, and highlight the need to understand the role of BMP-2 in primary hBMSCs derived from diverse sources in order to increase the efficiency of using BMP-2 in osteoinductive therapies.

KW - Alkaline phosphatase

KW - Bone morphogenic protein-2

KW - Human bone marrow stromal cells

KW - In vitro matrix mineralization

KW - Osteoblast differentiation

UR - http://www.scopus.com/inward/record.url?scp=49349107314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49349107314&partnerID=8YFLogxK

U2 - 10.1111/j.1440-169X.2008.01052.x

DO - 10.1111/j.1440-169X.2008.01052.x

M3 - Article

VL - 50

SP - 553

EP - 564

JO - Development Growth and Differentiation

JF - Development Growth and Differentiation

SN - 0012-1592

IS - 7

ER -